Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 6Completed 3Withdrawn 1Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Plasmablastic Lymphoma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 37Gemcitabine 31Paclitaxel 27Cisplatin 27Carboplatin 27Capecitabine 27camrelizumab 24Nivolumab 23apatinib 22Oxaliplatin 21fludarabine 20Radiotherapy 20toripalimab 17Immunotherapy, Adoptive 17Drug Therapy 17pembrolizumab 16Docetaxel 16Dexamethasone 15Bevacizumab 15N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 14Injections 14tislelizumab 13Temozolomide 13Rituximab 13Cetuximab 13Irinotecan 12130-nm albumin-bound paclitaxel 11anlotinib 10Fluorouracil 10Trastuzumab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Unknown × merphos × Clear all
NCT02481310 2022-02-21

Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma

Northwestern University

Phase 1/2 Unknown
38 enrolled 12 charts
Lymphoid

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡